Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes

    FRANKLIN, Mass., July 29 /CNW/ -- Echo Therapeutics (OTC Bulletin Board:  
ECTE) today announced positive results of a clinical study of its Symphony(TM)
Transdermal Continuous Glucose Monitoring (tCGM) System in patients with Type
1 and Type 2 Diabetes.  Echo's non-invasive Symphony tCGM System consists of
its wireless transmission and transdermal biosensor technologies and the
Prelude(TM) SkinPrep System, which incorporates leading-edge, needle-free skin
permeation control.  Echo's Symphony tCGM System is designed to provide both
diabetics and hospital patients with a reliable, affordable,
comfortable-to-wear, and easy-to-use, needle-free continuous glucose
monitoring device.
    "This study represents another major advancement in our Prelude and
Symphony development programs," stated Patrick Mooney, M.D., Echo's Chairman
and CEO. "We have now successfully used Prelude, our new needle-free skin
preparation system, in combination with our non-invasive Symphony tCGM
technology.  Data from this study demonstrate that Symphony, using Prelude, is
safe, accurate and reliable at monitoring glucose levels.  We look forward to
continuing progress with our Symphony development program throughout the
    Study Design
    After Prelude skin permeation, Symphony tCGM biosensors were applied to
ten subjects with Type 1 or Type 2 diabetes.  Venous reference blood samples
were taken from intravenous lines at 15-minute intervals for 24 hours and
measured on a YSI 2300STAT PLUS laboratory analyzer.  At the conclusion of the
24-hour observation period, the test skin sites were inspected for redness or
any other undesirable effects.
    Analytical Methods
    The primary statistical analysis tools used to evaluate the performance
of the Symphony tCGM System relative to the reference measurements were the
Clarke error grid, mean absolute relative difference (MARD) and linear
regression, each of which are widely used to evaluate the performance of
glucometers.  The Clarke error grid is a plot of all data pairs categorized
into five discrete areas: A, B, C, D and E. The A and B areas are the most
clinically desirable zones and D and E are the least clinically desirable
zones. Devices with a higher combined A and B zone percentage (closer to 100%)
and lower combined D and E zone percentage (closer to 0%) are considered to
have better performance. Continuous Glucose Monitoring (CGM) system
performance, including tCGM system performance, is competitive if at least
ninety-five percent (95%) of the data points fall within the combined A/B
zones, along with negligible or no data points in the combined D/E zones. Mean
absolute relative difference (MARD) is a standard error calculation tool that
is used to measure the average absolute value of the relative (or percentage)
difference between two measurements. A low MARD error, below 20%, is generally
considered competitive.
    Study Results
    Using 1,292 reference blood glucose measurements from the ten subjects in
the study, Clarke error grid analysis of the study data showed that Echo's
Symphony tCGM System had approximately 99% of the data in the combined A/B
zones, with 76.4% in the A zone and 22.4% in the B zone, and only 0.2% and
0.9% in the C zone and D zone, respectively.  The MARD for the study was
13.8%.  The correlation coefficient (R) for the data was 0.89.  There were no
adverse events reported from Prelude skin permeation or the Symphony tCGM
    Conference Call and Webcast Information
    Echo will host a conference call today at 11:00 AM ET to discuss the data
from its recent clinical study and to provide an update on its Symphony
development program. To access the conference call, please dial 866-394-4716
(domestic) or 706-634-5164 (international) and reference the conference ID
58102479. A replay of the call will be available from 12:00 PM. ET on July 29,
until August 12, 2008, at midnight. To access the replay, please dial
800-642-1687 (domestic) or 706-645-9291 (international) and reference the
conference ID 58102479. A live audio webcast of the call and the archived
webcast will be available in the Investors section of the Echo Therapeutics
website .
    About Echo Therapeutics
    Echo Therapeutics is focused on transdermal medical devices and specialty
pharmaceuticals. Echo is developing a non-invasive, wireless, transdermal
continuous glucose monitoring (tCGM) system for diabetics and for use in
hospital critical care units, together with a wide range of novel transdermal
reformulations of FDA-approved products.
    Forward Looking Statements
    Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current expectations,
but are subject to a number of risks and uncertainties. The factors that could
cause actual future results to differ materially from current expectations
include, but are not limited to, risks related to regulatory approvals and the
success of Echo's ongoing studies regarding the efficacy of Echo's Symphony
tCGM System, the failure of future development and preliminary marketing
efforts related to Echo's tCGM systems, risks and uncertainties relating to
Echo's ability to develop, market and sell diagnostic products based on its
skin permeation platform technologies, including the Prelude SkinPrep System,
the availability of substantial additional equity or debt capital to support
its research, development and product commercialization activities, and the
success of its research, development, and regulatory approval, marketing and
distribution plans and strategies, including those plans and strategies
related to its tCGM systems.
    These and other factors are identified and described in more detail in
Echo's filings with the Securities and Exchange Commission, including, without
limitation, its annual report on Form 10-KSB for the year ended December 31,
2007, its quarterly reports on Form 10-Q, and its current reports on Form 8-K.
The foregoing list of factors is not exhaustive. Echo Therapeutics, Inc.
undertakes no obligation to publicly update or revise any forward-looking

    Investor Relations Contacts:

    Patrick T. Mooney, M.D.
    Chairman & CEO
    Echo Therapeutics

    Melanie Friedman
    Stern Investor Relations


For further information:

For further information: Investors, Patrick T. Mooney, M.D., Chairman &
CEO of Echo Therapeutics, +1-508-530-0329; or Melanie Friedman of Stern
Investor Relations, +1-212-362-1200 Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890